CBS: Questions remain about COVID-19 booster shots
UC's Dr. Trisha Wise-Draper recommends third dose of mRNA vaccines to boost antibody production
While federal officials continue to analyze the need for the general public to receive a third dose of the currently available mRNA COVID-19 vaccines, certain immunocompromised groups are already eligible for a booster shot.
Dr. Trisha Wise-Draper, medical director of the UC Cancer Center's Clinical Trial Office and UC associate professor of medicine in the Division of Hematology/Oncology, said research has shown cancer patients in particular should receive a third dose as soon as possible.
"Certain cancer patients, especially those with blood disorders, are more at risk of not developing antibodies to the vaccine and remain vulnerable to the infection,” Wise-Draper told Local 12 News, in a story that was picked up nationally by news affiliates. "[Many patients] are at exceedingly high risk of serious disease and mortality from COVID-19."
Watch the full Local 12 report.
Featured photo at top: Shutterstock.com
Related Stories
Multi-institutional team awarded NCI grant to open novel AML...
June 23, 2025
The University of Cincinnati Cancer Center, The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and Jabez Biosciences are partnering to open a new phase 1 clinical trial studying JBZ-001, a potential new treatment for acute myeloid leukemia, funded by a National Cancer Institute grant.
Wrongfully convicted Ohioan awaits $45 million federal lawsuit...
June 22, 2025
The Cincinnati Enquirer speaks with Dean Gillispie, an Ohio Innocence Project exoneree, about compensation from Miami Township following a $45 million federal lawsuit for his wrongful conviction and incarceration.
Novel drug achieves high objective response rate in heavily...
June 18, 2025
Cancer Network News highlighted research led by the University of Cincinnati Cancer Center's Zulfa Omer that found a novel drug was generally well tolerated and demonstrated early efficacy in patients with relapsed/refractory chronic lymphocytic leukemia.